Acrivon Therapeutics, Inc. (ACRV) Stock Forecast
ACRV analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.57 / 5 from 7 analysts
- Price target
- $11.50 average of analyst targets
- Upside to target
- +601.2% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.45
- 52-week range
- $1.29 – $3.01
ACRV analyst ratings
7 analystsNumber of analysts at each rating.
ACRV price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ACRV earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.44 | −$0.48 | −$0.40 | −$0.47 | +6.8% | 5 |
| Current fiscal year (2026) | −$1.82 | −$2.03 | −$1.51 | −$2.02 | +10.1% | 5 |
| Next fiscal year (2027) | −$1.64 | −$2.13 | −$0.85 | −$1.82 | +9.6% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ACRV revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 7 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 7 |
ACRV EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ACRV EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.52 | −$0.52 | −$0.45 | −$0.45 | −$0.44 | −16.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$2.07 | −$2.07 | −$1.89 | −$1.89 | −$1.82 | −12.1% | 0 up · 0 down |
| Next fiscal year (2027) | −$1.95 | −$1.95 | −$1.69 | −$1.69 | −$1.64 | −15.8% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ACRV earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ACRV beat in 10 of 12.
What analysts expect from ACRV
7 analysts cover Acrivon Therapeutics; their consensus rating is strong buy (4.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.50, 601.2% above the latest close of $1.64. Analysts expect earnings of −$1.82 per share for 2026, +10.1% from a year earlier. For 2027 the average estimate is −$1.64 per share. Acrivon Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: ACRV income statement, ACRV key metrics, ACRV chart. See the ACRV stock overview for the latest quote and news.
ACRV forecast FAQ
What is Acrivon Therapeutics's price target?
The average analyst price target for Acrivon Therapeutics is $11.50, 601.2% above the latest close of $1.64.
Is Acrivon Therapeutics a buy, hold or sell?
Of 7 analysts covering Acrivon Therapeutics, 4 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Acrivon Therapeutics's EPS forecast?
Analysts forecast −$1.82 per share for 2026 (range −$2.03 to −$1.51); for 2027 the estimate is −$1.64.
When does Acrivon Therapeutics report earnings?
Acrivon Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.45.
Does Acrivon Therapeutics usually beat earnings estimates?
Acrivon Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.